CN102741245B - 苯并咪唑化合物及其用途 - Google Patents

苯并咪唑化合物及其用途 Download PDF

Info

Publication number
CN102741245B
CN102741245B CN201080061596.6A CN201080061596A CN102741245B CN 102741245 B CN102741245 B CN 102741245B CN 201080061596 A CN201080061596 A CN 201080061596A CN 102741245 B CN102741245 B CN 102741245B
Authority
CN
China
Prior art keywords
compound
formula
salt
methyl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080061596.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102741245A (zh
Inventor
L-D.坎丁
罗雪红
M.J.托马斯泽夫斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxosmithklay Intellectual Property No3 Co ltd
Original Assignee
Ni Aomeide Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ni Aomeide Research Institute filed Critical Ni Aomeide Research Institute
Publication of CN102741245A publication Critical patent/CN102741245A/zh
Application granted granted Critical
Publication of CN102741245B publication Critical patent/CN102741245B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201080061596.6A 2009-11-18 2010-11-17 苯并咪唑化合物及其用途 Active CN102741245B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26226309P 2009-11-18 2009-11-18
US61/262,263 2009-11-18
PCT/SE2010/051269 WO2011062550A1 (en) 2009-11-18 2010-11-17 Benzoimidazole compounds and uses thereof

Publications (2)

Publication Number Publication Date
CN102741245A CN102741245A (zh) 2012-10-17
CN102741245B true CN102741245B (zh) 2014-11-05

Family

ID=44059844

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080061596.6A Active CN102741245B (zh) 2009-11-18 2010-11-17 苯并咪唑化合物及其用途

Country Status (16)

Country Link
US (1) US8530467B2 (enExample)
EP (1) EP2501697B1 (enExample)
JP (1) JP5657018B2 (enExample)
KR (1) KR20120113709A (enExample)
CN (1) CN102741245B (enExample)
AR (1) AR079050A1 (enExample)
AU (1) AU2010322478B2 (enExample)
BR (1) BR112012011518B8 (enExample)
CA (1) CA2777746C (enExample)
ES (1) ES2442797T3 (enExample)
IN (1) IN2012DN03391A (enExample)
MX (1) MX2012005329A (enExample)
RU (1) RU2542582C2 (enExample)
TW (1) TW201121957A (enExample)
UY (1) UY33037A (enExample)
WO (1) WO2011062550A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158117A1 (en) * 2011-05-17 2012-11-22 Astrazeneca Ab Combination therapies for treating pain
WO2014117274A1 (en) * 2013-01-31 2014-08-07 Neomed Institute Imidazopyridine compounds and uses thereof
WO2015093586A1 (ja) * 2013-12-20 2015-06-25 塩野義製薬株式会社 トロンボポエチン受容体アゴニスト作用を有する光学活性な化合物およびその中間体の製造方法
WO2016004358A1 (en) 2014-07-03 2016-01-07 Afferent Pharmaceuticals, Inc. Methods and compositions for treating diseases and conditions
US10111883B1 (en) * 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
CN108904507A (zh) * 2018-02-11 2018-11-30 赖英杰 P2x3受体调节剂苯并咪唑化合物在制备抗呼吸疾病药物中的应用
KR102797127B1 (ko) * 2018-12-29 2025-04-21 우한 크리에이터나 사이언스 앤드 테크놀로지 컴퍼니, 리미티드 헤테로고리계 화합물, 중간체, 이의 제조 방법 및 용도
CN113727716A (zh) * 2019-02-25 2021-11-30 贝卢斯医疗咳嗽病公司 采用p2x3调节剂的治疗
BR112022015858A2 (pt) * 2020-02-14 2022-10-25 Bellus Health Cough Inc Composto, composição farmacêutica, e, métodos para tratar um distúrbio associado à atividade de p2x3, para tratar dor, para tratar um distúrbio do trato urinário, para reduzir ou prevenir a perda descontrolada de urina, para tratar tosse, para tratar prurido e para tratar endometriose, dor associada à endometriose e sintomas associados à endometriose
CA3187092A1 (en) * 2020-08-13 2022-02-17 Wenming Li Benzimidazole derivatives, preparation method therefor and medical use thereof
TW202227458A (zh) * 2020-12-04 2022-07-16 大陸商上海拓界生物醫藥科技有限公司 含有稠合三環的化合物及其醫藥用途
CN114478508A (zh) * 2021-12-31 2022-05-13 淮北师范大学 一种苯并咪唑化合物的结晶形式
TW202342468A (zh) * 2022-02-11 2023-11-01 大陸商江蘇恒瑞醫藥股份有限公司 P2x3受體拮抗劑的晶型及其製備方法
TW202337452A (zh) * 2022-02-11 2023-10-01 大陸商江蘇恒瑞醫藥股份有限公司 P2x3受體拮抗劑的藥用鹽及其製備方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060264490A1 (en) * 2004-09-24 2006-11-23 Astrazeneca Ab Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I
WO2008108958A2 (en) * 2007-03-02 2008-09-12 Schering Corporation Benzimidazole derivatives and methods of use thereof
WO2009058298A1 (en) * 2007-10-31 2009-05-07 Merck & Co., Inc. P2x3, receptor antagonists for treatment of pain

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6026A (en) * 1849-01-09 Cast-iron car-wheel
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
KR19990082463A (ko) 1996-02-13 1999-11-25 돈 리사 로얄 혈관 내피 성장 인자 억제제로서의 퀴나졸린유도체
AU719327B2 (en) 1996-03-05 2000-05-04 Astrazeneca Ab 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
SK288365B6 (sk) 1999-02-10 2016-07-01 Astrazeneca Ab Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy
DE60130865T2 (de) * 2000-01-17 2008-07-17 Teijin Pharma Ltd. Benzimidazol-derivate als menschliche chymase - inhibitoren
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
WO2002008213A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060264490A1 (en) * 2004-09-24 2006-11-23 Astrazeneca Ab Compounds, Compositions Containing Them, Preparation Thereof and Uses Thereof I
WO2008108958A2 (en) * 2007-03-02 2008-09-12 Schering Corporation Benzimidazole derivatives and methods of use thereof
WO2009058298A1 (en) * 2007-10-31 2009-05-07 Merck & Co., Inc. P2x3, receptor antagonists for treatment of pain

Also Published As

Publication number Publication date
AR079050A1 (es) 2011-12-21
ES2442797T3 (es) 2014-02-13
TW201121957A (en) 2011-07-01
MX2012005329A (es) 2012-05-29
CA2777746C (en) 2019-05-14
AU2010322478A1 (en) 2012-05-31
EP2501697A4 (en) 2013-04-24
CN102741245A (zh) 2012-10-17
JP5657018B2 (ja) 2015-01-21
BR112012011518B1 (pt) 2020-03-10
BR112012011518A2 (pt) 2016-06-28
UY33037A (es) 2011-06-30
US8530467B2 (en) 2013-09-10
CA2777746A1 (en) 2011-05-26
JP2013511517A (ja) 2013-04-04
EP2501697A1 (en) 2012-09-26
IN2012DN03391A (enExample) 2015-10-23
RU2542582C2 (ru) 2015-02-20
KR20120113709A (ko) 2012-10-15
US20120289504A1 (en) 2012-11-15
EP2501697B1 (en) 2013-10-23
RU2012124268A (ru) 2013-12-27
BR112012011518B8 (pt) 2023-01-10
AU2010322478B2 (en) 2013-11-14
WO2011062550A1 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
CN102741245B (zh) 苯并咪唑化合物及其用途
US9937185B2 (en) Imidazopyridine compounds and uses thereof
US20230406851A1 (en) Imidazopyridine compounds and uses thereof
HK1248138B (zh) 咪唑并吡啶化合物及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: NEOMED INSTITUTE

Free format text: FORMER OWNER: ASTRAZENECA AB

Effective date: 20141015

C14 Grant of patent or utility model
C41 Transfer of patent application or patent right or utility model
GR01 Patent grant
TA01 Transfer of patent application right

Effective date of registration: 20141015

Address after: Quebec

Applicant after: Neomed Institute

Address before: Swedish Sodertalje

Applicant before: ASTRAZENECA AB

CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: Quebec

Patentee after: NEOMED INSTITUTE

Address before: Quebec

Patentee before: Neomed Institute

EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20121017

Assignee: Berlus Health Co.,Ltd.

Assignor: NEOMED INSTITUTE

Contract record no.: 2018990000292

Denomination of invention: Benzoimidazole compounds and uses thereof

Granted publication date: 20141105

License type: Exclusive License

Record date: 20181109

EE01 Entry into force of recordation of patent licensing contract
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20220725

Address after: Quebec, CAN

Patentee after: Bellus medical cough Co.

Address before: Quebec, CAN

Patentee before: NEOMED INSTITUTE

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240606

Address after: Kaisan ohokkatsu

Patentee after: Silvio Berlusconi health Co.

Country or region after: Canada

Address before: Kaisan ohokkatsu

Patentee before: Bellus medical cough Co.

Country or region before: Canada

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240613

Address after: Kaisan ohokkatsu

Patentee after: 14245563 Canada Inc.

Country or region after: Canada

Address before: Kaisan ohokkatsu

Patentee before: Silvio Berlusconi health Co.

Country or region before: Canada

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240705

Address after: Kaisan ohokkatsu

Patentee after: ID BIOMEDICAL CORPORATION OF QUEBEC

Country or region after: Canada

Address before: Kaisan ohokkatsu

Patentee before: 14245563 Canada Inc.

Country or region before: Canada

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240716

Address after: Steve Niki

Patentee after: GlaxoSmithKlay Intellectual Property (No.3) Co.,Ltd.

Country or region after: Britain

Address before: Kaisan ohokkatsu

Patentee before: ID BIOMEDICAL CORPORATION OF QUEBEC

Country or region before: Canada